Bevacizumab, commonly known by its trade name Avastin, is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF). VEGF plays a crucial role in angiogenesis, the formation of new blood vessels, which is essential for tumor growth and metastasis. By inhibiting VEGF, bevacizumab can reduce the blood supply to tumors, thereby inhibiting their growth.
